miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026

Elon Musk's Terafab is here: What it is, and why it's important for Tesla and SpaceX

View original at finance.yahoo.com
Elon Musk's Terafab is here: What it is, and why it's important for Tesla and SpaceX Over the weekend in Austin, Texas, Tesla (TSLA) and SpaceX (SPAX.PVT) CEO Elon Musk unveiled what might be his grandest overarching vision for where he sees his companies headed…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Terafab is the most epic chip-building exercise in history by far

    60% confidence
  • Giga Texas alone is expected to have capacity for 10 million humanoid robots per year, which would require 20 million chips — approximately six times Tesla's current chip demand for its entire auto business

    60% confidence
  • Chipmakers like TSMC and Samsung aren't making chips fast enough for his companies' AI and robotics needs

    60% confidence
  • Goal is to produce more than a terawatt — 1 trillion watts — of AI computing power per year, with most of that capacity ultimately destined for space

    60% confidence
  • Current AI compute output is roughly 20 gigawatts per year and the rest of the world's output is about 2% of what his companies need

    60% confidence
  • Chipmakers' expansion rate is much less than what Musk's companies would like

    60% confidence
  • We either build the Terafab or we don't have the chips, and we need the chips, so we build the Terafab

    60% confidence

Data points we hold from this source

Elon Musk · ai compute output worldwide20 gigawatts_per_year
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com